DE60126072D1 - Auf lipiden basierende arzneistoffabgabesysteme zur topischen anwendung - Google Patents

Auf lipiden basierende arzneistoffabgabesysteme zur topischen anwendung

Info

Publication number
DE60126072D1
DE60126072D1 DE60126072T DE60126072T DE60126072D1 DE 60126072 D1 DE60126072 D1 DE 60126072D1 DE 60126072 T DE60126072 T DE 60126072T DE 60126072 T DE60126072 T DE 60126072T DE 60126072 D1 DE60126072 D1 DE 60126072D1
Authority
DE
Germany
Prior art keywords
lipid
topical application
based drug
drug dispensing
dispensing systems
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60126072T
Other languages
English (en)
Other versions
DE60126072T2 (de
Inventor
Kent Jorgensen
Jesper Davidsen
Charlotte Vermehren
Sven Frokjaer
G Mouritsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liplasome Pharma ApS
Original Assignee
Liplasome Pharma ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liplasome Pharma ApS filed Critical Liplasome Pharma ApS
Publication of DE60126072D1 publication Critical patent/DE60126072D1/de
Application granted granted Critical
Publication of DE60126072T2 publication Critical patent/DE60126072T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Cosmetics (AREA)
DE60126072T 2000-04-12 2001-04-11 Auf lipiden basierende arzneistoffabgabesysteme zur topischen anwendung Expired - Fee Related DE60126072T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK200000616 2000-04-12
DKPA200000616 2000-04-12
PCT/DK2001/000267 WO2001076555A2 (en) 2000-04-12 2001-04-11 Lipid-based drug delivery systems for topical application

Publications (2)

Publication Number Publication Date
DE60126072D1 true DE60126072D1 (de) 2007-03-08
DE60126072T2 DE60126072T2 (de) 2007-11-08

Family

ID=8159422

Family Applications (3)

Application Number Title Priority Date Filing Date
DE60122304T Expired - Fee Related DE60122304T2 (de) 2000-04-12 2001-04-11 Auf lipiden basierendes system zur zielgerichteten verabreichung diagnostischer wirkstoffe
DE60126072T Expired - Fee Related DE60126072T2 (de) 2000-04-12 2001-04-11 Auf lipiden basierende arzneistoffabgabesysteme zur topischen anwendung
DE60132184T Expired - Fee Related DE60132184T2 (de) 2000-04-12 2001-04-11 Auf lipiden basierende arzneistoffabgabesysteme gegen parasitäre infektionen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60122304T Expired - Fee Related DE60122304T2 (de) 2000-04-12 2001-04-11 Auf lipiden basierendes system zur zielgerichteten verabreichung diagnostischer wirkstoffe

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60132184T Expired - Fee Related DE60132184T2 (de) 2000-04-12 2001-04-11 Auf lipiden basierende arzneistoffabgabesysteme gegen parasitäre infektionen

Country Status (11)

Country Link
US (4) US20030170297A1 (de)
EP (3) EP1272225B1 (de)
JP (3) JP2003530338A (de)
AT (2) ATE336267T1 (de)
AU (3) AU2001248303A1 (de)
CY (2) CY1105792T1 (de)
DE (3) DE60122304T2 (de)
DK (3) DK1272225T3 (de)
ES (3) ES2280355T3 (de)
PT (3) PT1272161E (de)
WO (3) WO2001076556A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020001614A1 (en) * 2000-02-10 2002-01-03 Kent Jorgensen Lipid-based drug delivery systems containing phospholipase A2 degradable lipid derivatives and the therapeutic uses thereof
WO2002085391A1 (es) * 2001-04-24 2002-10-31 Luis Alberto Costa Uso de una fosfolipasa a2 para la preparacion de composiciones farmaceuticas y/o cosmeticas para la prevencion y/o el tratamiento local y/o sistemico de enfermedades y/o procesos provocados por patogenos intra y extracelulares que expresen fosfolipidos de membrana
US20050123925A1 (en) * 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20050112065A1 (en) * 2003-07-09 2005-05-26 Drummond Daryl C. Remote detection of substance delivery to cells
US20050266066A1 (en) * 2003-10-20 2005-12-01 Nof Corporation Phospholipid membrane preparation
WO2005077963A1 (fr) * 2004-01-16 2005-08-25 Institut Superieur Agricole De Beauvais DErivEs de saccharides et d'itols possEdant un groupement O-alkyle ou un groupement O-alkyle et un groupement O-n-butanoyle. Applications comme mEdicaments dans les pathologies prolifEratives tumorales ou bEnignes.
US20080113014A1 (en) * 2004-01-28 2008-05-15 Ltt Bio-Pharma Co., Ltd. Method for Screening for Compounds Safe for Gastric Mucosa
DE102004010387A1 (de) * 2004-03-03 2005-09-22 Siemens Ag Kontrastmittel für die Röntgen-Computertomographie
WO2006086992A2 (en) * 2005-02-18 2006-08-24 Liplasome Pharma A/S Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
US20090110633A1 (en) * 2005-03-14 2009-04-30 Shiladitya Sengupta Nanocells for Diagnosis and Treatment of Diseases and Disorders
PL1933809T3 (pl) * 2005-10-11 2012-09-28 Yissum Research Development Company Of The Hebrew Univ Of Jerusalem Kompozycje do dostarczania donosowego
WO2007071402A1 (en) * 2005-12-23 2007-06-28 Jado Technologies Gmbh Means and methods for the treatment and prevention of allergic diseases
JP2011026294A (ja) * 2009-06-26 2011-02-10 Canon Inc 化合物
US8993715B2 (en) * 2009-07-06 2015-03-31 Canon Kabushiki Kaisha Labeled protein and method for obtaining the same
DE112010003355T5 (de) 2009-08-21 2012-07-12 Targeted Delivery Technologies Ltd. Veskuläre Formulierungen
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
DK177529B1 (en) * 2009-10-23 2013-09-08 Bio Bedst Aps Liposomes with improved storage stability
WO2011102905A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion diagnostic delivery system
WO2011102906A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion delivery system
WO2011102904A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion therapeutic delivery system
JP2015509507A (ja) * 2012-03-09 2015-03-30 ウニベルシダーヂ フェデラル ヂ ミナス ジェライス−ウエフィエミジェー 内臓リーシュマニア症を治療するための従来型リポソームと長期循環型リポソームを含有する医薬組成物
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
WO2014047116A1 (en) * 2012-09-18 2014-03-27 Comfort Care For Animals Llc Encapsulating liposomes
LT3316856T (lt) 2015-06-30 2021-07-12 Sequessome Technology Holdings Limited Mišrios kompozicijos
WO2018087720A1 (en) 2016-11-14 2018-05-17 Novartis Ag Compositions, methods, and therapeutic uses related to fusogenic protein minion

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0714865B2 (ja) * 1986-10-28 1995-02-22 武田薬品工業株式会社 リポソ−ム製剤およびその製造法
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5925375A (en) * 1987-05-22 1999-07-20 The Liposome Company, Inc. Therapeutic use of multilamellar liposomal prostaglandin formulations
FR2638639A1 (fr) * 1988-11-08 1990-05-11 Parincos Parfumerie Cosmet Int Composition et procede d'obtention de liposomes oligolamellaires en vue d'une application en cosmetologie et dermatologie topique
US5153000A (en) * 1988-11-22 1992-10-06 Kao Corporation Phosphate, liposome comprising the phosphate as membrane constituent, and cosmetic and liposome preparation comprising the liposome
US4874794A (en) * 1989-04-28 1989-10-17 Lidak Biopharmaceuticals Inflammatory disease treatment
JPH0370491A (ja) 1989-08-04 1991-03-26 Toshiba Corp 電動機制御装置
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5705187A (en) * 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
CA2067754C (en) * 1990-08-24 2002-06-04 Gregor Cevc Preparation for the application of agents in mini-droplets
US5723115A (en) * 1991-05-02 1998-03-03 W. Alton Jones Cell Science Center, Inc. Inhibition of adipose tissue development and obesity
US5484911A (en) * 1993-04-01 1996-01-16 Health Research, Inc. Nucleoside 5'-diphosphate conjugates of ether lipids
DE4408011C1 (de) * 1994-03-10 1995-11-02 Max Delbrueck Centrum Pharmazeutisches Mittel zur Tumortherapie
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
US5942246A (en) * 1996-02-16 1999-08-24 The Liposome Company, Inc. Etherlipid containing multiple lipid liposomes
US5827836A (en) 1996-11-15 1998-10-27 Clarion Pharmaceuticals Inc. Retinoid glycerol phospholipid conjugates
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6048736A (en) * 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6444640B1 (en) * 1999-09-30 2002-09-03 Ludwig Institute For Cancer Research Compositions of trail and DNA damaging drugs and uses thereof

Also Published As

Publication number Publication date
US20030162748A1 (en) 2003-08-28
WO2001076555A2 (en) 2001-10-18
US7368254B2 (en) 2008-05-06
WO2001076644A2 (en) 2001-10-18
ES2270991T3 (es) 2007-04-16
PT1272160E (pt) 2007-04-30
US20070134153A1 (en) 2007-06-14
WO2001076556A3 (en) 2002-07-11
EP1272225B1 (de) 2006-08-16
AU2001248302A1 (en) 2001-10-23
ATE336267T1 (de) 2006-09-15
EP1272160B1 (de) 2007-01-17
JP2003530339A (ja) 2003-10-14
EP1272161A2 (de) 2003-01-08
DK1272160T3 (da) 2007-05-21
WO2001076555A3 (en) 2002-03-14
JP2003530338A (ja) 2003-10-14
EP1272161B1 (de) 2008-01-02
PT1272161E (pt) 2008-02-08
DK1272161T3 (da) 2008-05-19
DE60122304D1 (de) 2006-09-28
JP2003530362A (ja) 2003-10-14
AU2001248301A1 (en) 2001-10-23
ES2280355T3 (es) 2007-09-16
WO2001076556A2 (en) 2001-10-18
US20030170297A1 (en) 2003-09-11
US7166297B2 (en) 2007-01-23
US20030175205A1 (en) 2003-09-18
PT1272225E (pt) 2007-01-31
CY1105792T1 (el) 2011-02-02
CY1106462T1 (el) 2012-01-25
ATE382333T1 (de) 2008-01-15
DE60122304T2 (de) 2007-08-09
DE60132184D1 (de) 2008-02-14
AU2001248303A1 (en) 2001-10-23
DK1272225T3 (da) 2006-12-27
DE60132184T2 (de) 2009-01-15
ES2295149T3 (es) 2008-04-16
EP1272160A2 (de) 2003-01-08
DE60126072T2 (de) 2007-11-08
WO2001076644A3 (en) 2002-03-14
EP1272225A2 (de) 2003-01-08

Similar Documents

Publication Publication Date Title
DE60126072D1 (de) Auf lipiden basierende arzneistoffabgabesysteme zur topischen anwendung
BRPI0518228B8 (pt) inibidores de cinesina mitótica e uso dos mesmos
GB0222495D0 (en) Compounds
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
EA200700934A1 (ru) Производные пиримидина и их применение в качестве модуляторов cb2
TW200611695A (en) Pyrrolopyridine derivatives
ES2163034T3 (es) Composiciones micelares de copolimeros de bloque de polieter, para la objetivizacion de agentes biologicos como diana.
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
ATE478141T1 (de) Durch phagendisplay identifizierte zielpeptide des menschen und der maus
BR0115102A (pt) 1-aril- ou 1-alquilsulfonil-heterociclilbenzazóis como ligantes 5-hidroxitriptamina-6
DZ3265A1 (fr) Derives de 4,5-diaryl-3(2h)-furanone comme inhibiteurs de cyclo-oxygenase-2
BRPI0410649A (pt) benzo(b) tiofeno 3-arilóxi e 3-heteroarilóxi substituìdos como agentes terapêuticos com atividade pi3k
GT200300294A (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
TW200801031A (en) Steroid nitrooxyderivatives
ATE273690T1 (de) Zusammensetzung zur hautdesinfizierung
PA8553101A1 (es) Formulaciones en combinacion de derivados de propanol-amina sustituidos con arilo, junto con otras sustancias activas y su utilizacion
BR0009211A (pt) Derivados de resorcinol
ATE556134T1 (de) Mesenchymstammzellen und verwendungendafür
BRPI0507632A (pt) compostos e composições como moduladores de lxr
BRPI0408889A (pt) uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas
BRPI0508053A (pt) método de combater toxicidade causada por um composto antifolato, e de tratar uma doença, usos de enzima que possui atividade de carbóxi-peptidase g, de composto antifolato, de agente de resgate de rota de folato, e de enzima que possui atividade de carbóxi-peptidase g e de um agente de resgate de rota de folato, sistema terapêutico, e, método ex vivo de clivar um grupo l-glutamato terminal de um composto, de determinar a taxa e/ou extenção de clivagem de um composto, e de clivagem de um composto
BR0009194A (pt) Composição do resorcinol
BR9911885A (pt) Inibidores da angiogênese
BR0010699A (pt) Benzimidazóis substituìdos, sua produção e utilização dos mesmos como agente contra protozoários parasitários
WO2020198662A8 (en) Clec9a-based chimeric protein complexes

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee